» Educational Qualifications

» Academic Titles

» Publications

SCI-SSCI or SCI Expanded Articles

  • Incidence and predisposing factors of infection in patients treated with hypomethylating agents, Leukemia Research, ALP KIRKIZLAR TUGCAN, KIRKIZLAR HAKKI ONUR, DEMIRCI UFUK, UMUT AYTUG, IFLAZOGLU HÜSEYIN, ÜMIT ELIF GÜLSÜM, DEMIR AHMET MUZAFFER, vol. 127, no. 107043, pp. 1-6, 2023 (April 2023)
    3
    ATIF
  • The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: a retrospective study (February 2022)
    1
    ATIF
  • .BAYSAL MEHMET, GÜRSOY VILDAN, HUNUTLU FAZIL ÇAGRI, ERKAN ÖZMARASALI BUKET, DEMIRCI UFUK, BAS VOLKAN, KARAMAN GÜLSARAN SEDANUR, PINAR IBRAHIM ETHEM, ERSAL TUBA, ALP KIRKIZLAR TUGCAN, ATLI EMINE IKBAL, KIRKIZLAR HAKKI ONUR, ÜMIT ELIF GÜLSÜM, GÜRKAN HAKAN, ÖZKOCAMAN VILDAN, ÖZKALEMKAS FAHIR, DEMIR AHMET MUZAFFER, ALI RIDVAN, The evaluation of risk factors leading to early deaths in patients with acute promyelocytic leukemia: a retrospective study, Annals of Hematology, vol. 101, pp. 1049-1057, 2022.
  • Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia (October 2020)
    6
    ATIF
  • The Incidence of Venous Thromboembolism and Impact on Survival in Hodgkin Lymphoma (March 2020)
    10
    ATIF
  • .KIRKIZLAR HAKKI ONUR, ALP KIRKIZLAR TUGCAN, ÜMIT ELIF GÜLSÜM, ASKER ISMAIL, BAYSAL MEHMET, BAS VOLKAN, KARAMAN GÜLSARAN SEDANUR, DEMIRCI UFUK, DEMIR AHMET MUZAFFER, The Incidence of Venous Thromboembolism and Impact on Survival in Hodgkin Lymphoma, CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 20, no. 8, pp. 542-547, 2020.
  • .ALP KIRKIZLAR TUGCAN, AKALIN EMIN HALIS, KIRKIZLAR HAKKI ONUR, ÖZKALEMKAS FAHIR, ÖZKOCAMAN VILDAN, KAZAK ESRA, ÖZAKIN CÜNEYT, BÜLBÜL ESRA NUR, ÖZBOZ EZGI SEZEN, ALI RIDVAN, Vancomycin-resistant enterococci infection and predisposing factors for infection and mortality in patients with acute leukaemia and febrile neutropenia, LEUKEMIA RESEARCH, vol. 99, no. 106463, pp. 1-5, 2020.
  • .B. Koc, F. Tutal, M. Urumdas, Y. Ozkurt, T. Erus, A. Yavuz, O. Kemik, The Preliminary Experience in the Emergency Department of a Newly Opened Penitentiary Institution Hospital in Turkey, 10.4103/1947-2714.141642, NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES, vol. 6, no. 9, pp. 460-465, 2014.
  • .C. Meral, M. Aktuglu, H. Hassoy, Z. Karaali, T. Alioglu, O. Kirkizlar, S. Acar, M. Kendir, S. Erez, T. Erus, S. Sayilan, The Relationship Between Factor VIII and Coronary Artery Diseases, 10.4274/Haseki.726, HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, vol. 50, no. 4, pp. 113-118, 2012.

International Articles

  • Venetoclax is a drug commonly associated with tumor lysis syndrome (TLS) and electrolyte imbalances. However, its effects on electrolyte metabolism are not limited to TLS. We present a patient with relapsed chronic lymphocytic leukemia who experienced electrolyte imbalances as grade 2 hypocalcemia, hypophosphatemia, and hypomagnesemia during the venetoclax escalation period, independent of TLS or renal or gastrointestinal loss. The patient was successfully managed with close electrolyte monitoring and appropriate electrolyte replacement without discontinuing venetoclax. There is limited data on electrolyte imbalances associated with venetoclax other than TLS. Studies show the incidence and severity of electrolyte imbalances, but managing these adverse events is not clear enough. Therefore, we would like to share our approach and experience with a patient who developed venetoclax-induced hypocalcemia, hypophosphatemia, and hypomagnesemia. (October 2024)
  • Evaluation of leukapheresis and leukapheresis with additional cytoreduction in acute leukemia with hyperleukocytosis, ALP KIRKIZLAR TUGCAN, DEMIR AHMET MUZAFFER, Turkish Journal of Internal Medicine, vol. 5, no. 3, pp. 191-198, 2023 (July 2023)
  • Comparison of Hemophagocytic Lymphohistiocytosis Diagnostic Criteria in Malignancy-Associated Hemophagocytic Lymphohistiocytosis Patients (December 2022)
  • The incidence of osteoporosis and vertebral fracture in women with postmenopausal type 2 diabetes mellitus and predisposing factors of vertebral fractures (July 2021)
    1
    ATIF
  • .ALP KIRKIZLAR TUGCAN, AKTUGLU MEHMET BURAK, The incidence of osteoporosis and vertebral fracture in women with postmenopausal type 2 diabetes mellitus and predisposing factors of vertebral fractures, The International Journal of Advances in Medicine, vol. 8, no. 10, pp. 1478-1482, 2021.

International Conference Proceedings

  • THE INCIDENCE OF INFECTIONS AND ITS EFFECTS ON MORTALITY IN AML PATIENTS TREATED WITH VENETOCLAX. P2219. AVRUPA HEMATOLOJİ KONGRESİ 2024 (June 2024)
  • P977: THE VENOUS THROMBOEMBOLISM RISK ASSESMENT MODELS IN MULTIPLE MYELOMA Alp Kirkizlar, Tugcan1; Kirkizlar, Onur1; Muzaffer Demir, Ahmet1; Gulsum Umit, Elif1 Author Information HemaSphere 7(S3):p e2045172, August 2023. | DOI: 10.1097/01.HS9.0000970812.20451.72 (August 2023)
  • O-11: Evaluation of Indications, Complications, Outcomes and Hospital Mortality of TPE Applied Patients (September 2022)
  • .V. Ozkocaman, F. Ozkalemkas, R. Ali, Y. Karacan, T. Ersal, H. Gozden, T. Erus, E. Kazak, H. Akalin, Oral Valganciclovir As Preemptive Therapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplant Recipients, BLOOD, vol. 124, no. 21, pp. , 2014. (December 2014)
    1
    ATIF

National Articles

  • Abstract: In acute myeloid leukaemia (AML), which the median age at diagnosis is 68 years, survival is significantly lower in the elderly group who are ineligible for intensive treatment. Survival and quality of life have been improved with the combination of the hypomethylating agent venetoclax (HMA-V), which has become the standard of care for this group of patients. We aimed to evaluate the results of HMA-V combination therapy in the group of AML patients who are ineligible for intensive treatment at our centre. The median age of the 37 patients included in the study was 70.2 years, and 51.4% were women. 73% of the patients were de novo leukemia while 4 patients were relapse and 1 was refractory disease. The HMA-V combination was given 2 patients who were in remission due to intolerance/side effects of intensive treatment. Azacitidine usage rate was 78.6%. The median number of course was 3. The remission rate was found to be 51.4% in bone marrow evaluation at the end of the 1st/2nd course. The mean follow-up was 11.9 months and 56.75% of patients died. Mean survival was 27.1, 4.1 and 7.5 months for those who achieved remission, those who did not achieve remission and those who could not be assessed, respectively, with a significant difference between groups (p <0.001). While mean and median survival with azacitidine were 22.03 and 23 months, with decitabine 3.87 and 3 months respectively, there was a significant statistical difference (p<0.001). In multivariate Cox regression analysis, the only factor influencing mortality was not being in remission at the end of 1st/2nd cycle assessment. In conclusion, the survival and remission rates seen in our center are found to be similar to real-world studies. Keywords: Acute Myeloid Leukemia, Azacitidine, Decitabine, Venetoclax https://doi.org/10.20515/otd.1436206 (February 2024)
  • Retrospective Analysis of Extranodal Involvement of Head and Neck Diffuse Large B Cell Lymphomas and Comparison of Nodal Disease (October 2021)
  • .KIRKIZLAR HAKKI ONUR, ALP KIRKIZLAR TUGCAN, DEMIRCI UFUK, KARAMAN GÜLSARAN SEDANUR, BAS VOLKAN, ÜMIT ELIF GÜLSÜM, DEMIR AHMET MUZAFFER, Ekstranodal Bas Boyun Diffüz Büyük B Hücreli Lenfomalarinin Geriye Yönelik Olarak Degerlendirilmesi ve Nodal Hastalik ile Karsilastirilmasi, LLM Dergi, vol. 5, no. 2, pp. 21-26, 2021.
  • .ALP KIRKIZLAR TUGCAN, ÇALAPKULU MURAT, GÖMLEKSIZ MUHAMMET RIDVAN, ÖZKALEMKAS FAHIR, ÖZKOCAMAN VILDAN, ALI RIDVAN, TÜZÜNER TUNÇAY NURIYE NUKHET, Case Report of a Rare Disease: Kimura Disease, Turkiye Klinikleri, vol. 3, no. 1, pp. 39-42, 2018.

National Conference Proceedings

  • TRAKYA üNİVERSİTESİ KAN MERKEZİ 5 YILLIK HEMOVİJİLANS VERİLERİ. TP-22/361. 50. ULUSAL HEMATOLOJİ KONGRESİ (November 2024)
  • SS-37 Referans Numarası: 154 YENİ TANILI ERİŞKİN AKUT MİYELOİD LÖSEMİLİ HASTALARDA HÜCRE PROLİFERASYONU, HÜCRE FARKLILAŞMASI VE APOPİTOZİS ÜZERİNE ETKİLİ UZUN KODLAMAYAN RNA’LARIN ARAŞTIRILMASI Ebru Göncü4, Hakkı Onur Kırkızlar2, Hakan Gürkan1, Tuğcan Alp Kırkızlar2, Elif Gülsüm Ümit2, Ahmet Muzaffer Demir2, Jülide Tozkır3 50. ULUSAL HEMATOLOJİ KONGRESİ (November 2024)
  • Multiple Miyelom Tanılı Hastalarda Tedavideki Yeni Yaklaşımlar Sonrası Yaşam Kalitesinin Qly-30 Ve Myc-20 Kriterlerine Göre Değerlendirilmesi (November 2023)

National Conferences and Symposiums

  • SS-30 Referans Numarası: 352 AML’DE HMA VENETOKLAKS KOMBİNASYONUNDA ANTİFUNGAL PROFİLAKSİ VE VENETOKLAKS KULLANIMI- THD HEMATOLOJİDE ENFEKSİYONLAR VE DESTEK TEDAVİLER ALT KOMİTESİ ANKET ÇALIŞMASI Tuğcan Alp Kırkızlar1, Vildan Özkocaman2 Türk Hematoloji Derneği 50. Ulusal Hematoloji Kongresi 2024 (November 2024)
  • S21- ERİŞKİN AKUT LENFOBLASTİK LÖSEMİDE SAĞKALIMA ETKİ EDEN FAKTÖRLER Tuğcan Alp Kırkızlar1 EHOK 2024 Sözlü Sunum (March 2024)

National Books and Book Chapters

  • TIP HEKİMİNİN SON TEKRARLARI Editörler:TABAKOĞLU ERHAN, GÜDÜCÜOĞLU HÜSEYİN, PARLAK MEHMET ISSN:978-975-374-370-9 Talasemiler (January 2024)
  • TIP HEKİMİNİN SON TEKRARLARI Editörler:TABAKOĞLU ERHAN, GÜDÜCÜOĞLU HÜSEYİN, PARLAK MEHMET ISSN:978-975-374-370-9 Demir Eksikliği Anemisi (January 2024)
  • Klinik pratikte hematolojik hastalıklara yaklaşım, Kan transfüzyonu endikasyonları ve komplikasyonlar (December 2021)

Editorial Positions

  • BALKAN MEDICAL JOURNAL EDITORIAL BOARD MEMBER 2024 (December 2024)

Referee Positions

  • OPTIMIZING AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTPLE MYELOMA BALKAN MED J-2024-11-132 (December 2024)
  • POSACONAZOLE THERAPEUTIC DRUG MONITORING IN DAILY PRACTICE-TJH-2024-0458 (December 2024)
  • EVALUATION OF THE EFFECTS OF REGULATORY T CELLS ON SURVIVAL OUTCOMES IN PATIENTS WITH ACUTE LEUKEMIA WHO DEVELOPED FEBRILE NEUTROPENIA TJMED-2024-01962 (October 2024)
  • Pre-publication review Canonical URL: https://publons.com/wos-op/review/author/3ACdqi4N/ Code: 3ACdqi4N Performed for: Clinical Medicine Insights: Oncology (journal) Verification: YES. Verified by journal integration Date Date of review: 2024 (July 2024)
  • Review date: 2024 Type: reviewRole: reviewer Show less detailView Review identifier(s) SOURCE-WORK-ID: f500494f-c95a-441c-9a28-e63817e5b7ad Convening organization Elsevier, Inc. (New York, US) Source : Elsevier Editorial (June 2024)
  • Review date: 2024 Type: reviewRole: reviewer Show less detailView Review identifier(s) SOURCE-WORK-ID: 3ccb814a-f96b-4f1c-9f8a-83006f4e35e8 Convening organization Elsevier, Inc. (New York, US) Source : Elsevier Editorial (June 2024)
  • Review date: 2024 Type: reviewRole: reviewer Show less detailView Review identifier(s) SOURCE-WORK-ID: 304ca6b8-549b-47e4-8ab0-2d72c6d4b78a Convening organization Elsevier, Inc. (New York, US) Source : Elsevier Editorial (May 2024)
  • THE IMPORTANCE OF TP53 STATUS IN CART THERAPHY:THE EXAMPLE OF CLL. LEUKEMİA RESEARCH. NOV 2023 (November 2023)
  • THE IMPACT OF VENETOCLAX ON EARLY MORTALITY IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA SEP 2023 LEUKEMIA RESEARCH (September 2023)
  • SINGLE CENTER RETROSPECTIVE ANALYSES OF EXTRACORPOREAL PHOTOPHERESIS THERAPHY IN PATIENTS HEAVILY PRETREATED FOR CHRONIC GVHD WITH STEROID FAILURE. LEUKEMIA RESEARCH. SEP 2023 (September 2023)
  • AML WITH CEBPA MUTATIONS: A COMPARISION OF ICC AND WHO HAEM5 CRITERIA IN PATIENTS WITH>%20 BLASTS. LEUKEMIA RESEARCH AGU 2023 (August 2023)
  • MYC Overexpression is Associated with an Early Disease Progression from MDS to AML (October 2021)
  • Clinicopathological characteristics and possible prognostic factors of lymphoepithelioid cell lymphoma (Lennert lymphoma) LR-D-21-00273 (May 2021)

Other

  • WEB OF SCIENCE H INDEX 3 (December 2024)
  • ALP KIRKIZLAR TUGCAN, KIRKIZLAR HAKKI ONUR, Iç Hastaliklari 2 Cilt, 4. Baski, Günes Kitapevi, Ankara-TÜRKIYE PROLENFOSİTİK LÖSEMİ BÖLÜMÜ (January 2024)
  • .ALP KIRKIZLAR TUGCAN, KIRKIZLAR HAKKI ONUR, Iç Hastaliklari 2 Cilt, 4. Baski, Günes Kitapevi, Ankara-TÜRKIYE.
  • H İNDEX 3 PUAN (January 2023)
  • H İNDEKSİ 2 PUAN
  • .T. Alp, V. Ozkocaman, F. Ozkalemkas, C. Sanli, H. Gozden, Z. Yegen, R. Ali, A CASE OF AN ANTITHROMBIN DEFICIENCY WITH MESENTERIC THROMBOSES AND CEREBRAL INFARCT, THROMBOSIS RESEARCH, vol. 141, pp. S76-S76, 2016.
  • .V. Ozkocaman, F. Ozkalemkas, B. Cilo, T. Alp, T. Ersal, E. Gozden, Z. Yegen, A. Ridvan, B. Ener, Invasive Fusariosis in Patients with Hematologic Malignancies at a University Hospital, BLOOD, vol. 126, no. 23, pp. , 2015.